

Special Issue

Molecular Biomarkers in Alzheimer's Disease

Message from the Guest Editor

Alzheimer's disease (AD) is a leading cause of death without effective treatments available. Biomarker studies are essential for the identification of a robust strategy for developing effective prevention, accurate diagnosis, and novel treatments for mild cognitive impairment (MCI), Alzheimer's disease, and Alzheimer's-disease-related dementias (ADRDs). The suitable topics for this Special Issue include but are not limited to:

Genetic, transcriptomic, and epigenetic variants, eQTL, QTL, pathways, or gene networks associated with the risk or rate of progression of ADRD.

Genomic, proteomic or multi-omic analysis of blood-based, CSF-based, or vascular biomarkers of neuroinflammation, neurodegeneration and risk of MCI or ADRD.

Gene–environment and gene–lifestyle factor interactions and the prevention of neurodegeneration, MCI, or ADRD.

Biomarkers of chronic mental-health disorders or sleep disorders for the risk of MCI or ADRD.

Biomarkers or polygenic models for the prevention and treatment of MCI or ADRD.

Biomarkers of longevity, normal aging, and age at onset of MCI or ADRD.

Guest Editor

Prof. Dr. Yongzhao Shao

Department of Population Health, New York University Grossman School of Medicine, New York, NY 10016, USA

Deadline for manuscript submissions

closed (25 July 2023)

G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



mdpi.com/si/107386

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Experimental Cancer Therapeutics, The University of Alabama at
Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-
2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))